Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences

Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at significantly lower concentrations than the plasma trough levels achieved by the dosage adopted for influenza treatment and exhibits effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraki, Kimiyasu, Sato, Noriaki, Sakai, Kaoru, Matsumoto, Shirou, Kaszynski, Richard H., Takemoto, Masaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806403/
https://www.ncbi.nlm.nih.gov/pubmed/35121001
http://dx.doi.org/10.1016/j.pharmthera.2022.108121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806403/
https://www.ncbi.nlm.nih.gov/pubmed/35121001
http://dx.doi.org/10.1016/j.pharmthera.2022.108121

Ejemplares similares